OncoMatch/Clinical Trials/NCT05305131
Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer
Is NCT05305131 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including cisplatin and gemcitabine and induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab. for nasopharyngeal cancer.
Treatment: cisplatin and gemcitabine · induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab. — The investigators hypothesize that the addition of bevacizumab and pembrolizumab to induction cisplatin and gemcitabine is tolerable and improves metabolic complete response (mCR), relapse free survival (RFS) and overall survival (OS) compared to induction cisplatin and gemcitabine in patients with locally advanced nasopharyngeal cancer (NPC)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: EBV EBV-encoded small RNA positive by EBER in situ hybridization
locally or centrally determined EBV-positive NPC by EBV-encoded small RNA in situ hybridization (EBER in situ hybridization [ISH]) assay
Disease stage
Required: Stage III, IVA (AJCC 8th edition)
Excluded: Stage III T3N0, III T3N1
Tumour stage III (except for T3N0 and T3N1) or IVA according to the American Joint Committee on Cancer (AJCC) 8th edition criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic anti-cancer therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05305131 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EBV?
Yes, EBV EBV-encoded small RNA positive by EBER in situ hybridization is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IVA is required.
Is there an age limit?
Yes. Patients must be 99 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages